Click below to learn more about Decipher.
Understand your risk. Personalize your treatment plan.
- Is active surveillance sufficient for me?
- Is localized treatment sufficient?
- Do I need more than one therapy [multi-modal therapy]?
The Decipher Biopsy test is the most accurate way to determine aggressiveness of your prostate cancer and assess your personal risk of metastasis. Using advanced whole genome technology, Decipher Biopsy provides valuable information to you and your doctor so that you can make more informed decisions about your next steps in managing your prostate cancer.
Decipher® Your Risk of Recurrence...
Decipher® is a transformative genomic test that informs decisions about the course of treatment for men after prostate surgery.
For patients, this means a personalized assessment of your risk of prostate cancer recurrence after prostatectomy.
Decipher measures the activity of certain genes in the tumor that are known to be involved in the development and progression of prostate cancer to tell you more about how your cancer may behave and develop.
The test analyzes a small tissue sample that was removed during surgery and is routinely archived or stored by the pathology laboratory. No additional procedures are required.
The Decipher Bladder Test Helps You and Your Doctor Make a Personalized Decision in Your Bladder Cancer Care
Based on each patient’s individual tumor genomics, Decipher Bladder:
- Identifies which patients with muscle invasive bladder cancer may benefit from neoadjuvant chemotherapy prior to radical cystectomy.
Decipher Bladder predicts which patients with Muscle Invasive Bladder Cancer:
- May benefit from neoadjuvant chemotherapy prior to bladder removal surgery (radical cystectomy)
- May benefit from immediate bladder removal surgery (radical cystectomy)
How Decipher Bladder Works:
- Perform advanced genomic testing on your pathology specimen from transurethral resection of bladder tumor (TURBT) procedure (Patients do not have to undergo any further procedures for Decipher Bladder)
- Classify your bladder tumor sample into one of four molecular subtypes
- One of four molecular subtypes have implications for distinct therapeutic decision making for patients and their physicians
Seiler, R., et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival outcome to neoadjuvant chemotherapy: results from a multi-institutional validation study. Presented at the Annual Meeting of the Society of Urologic Oncology, 2016